Abstract: Regadenoson stress CMR is safe and well tolerated in heart transplant recipients, with no incidence of sinus node dysfunction or high-degree atrioventricular block, including in the first two years after heart transplantation. An abnormal regadenoson stress CMR identifies heart transplant recipients at a higher risk for major adverse cardiovascular events.
Introduction: The Challenge of Silent Coronary Allograft Vasculopathy
Heart transplant recipients face a persistent threat known as coronary allograft vasculopathy (CAV), an accelerated form of coronary artery disease affecting the donor heart. Because the transplanted heart is denervated during surgery, patients often do not experience the typical chest pain (angina) that signals cardiac distress, making CAV a "silent killer."
Currently, monitoring relies on invasive procedures like coronary angiography and intravascular ultrasound. While effective, these methods carry risks of radiation exposure, kidney injury from contrast dye, and procedural complications. Non-invasive stress tests are a potential alternative; however, the standard vasodilator, adenosine, is contraindicated in this population due to the "super-sensitivity" of denervated hearts, which can lead to dangerous bradycardia or heart block. This study investigates whether regadenoson, a selective $A_{2A}$ adenosine receptor agonist, offers a safer and more predictive alternative.
Methods and CMR Protocol
Researchers at the University of Minnesota conducted a retrospective matched cohort study analyzing 78 regadenoson stress CMR studies performed on 57 heart transplant recipients. These were compared to 156 age- and gender-matched non-transplant controls.
The CMR protocol included:
- Cine CMR: Assessment of resting cardiac function.
- Stress Perfusion: Administration of 0.4 mg regadenoson followed by gadolinium contrast to visualize myocardial blood flow.
- Rest Perfusion: Baseline blood flow imaging.
- Late Gadolinium Enhancement (LGE): Detection of myocardial scarring or fibrosis.
Patients were monitored for adverse effects, and major adverse cardiovascular events (MACE)—including myocardial infarction, retransplantation, hospitalization, or death—were tracked over a median follow-up of 1.3 years.
Safety and Prognostic Outcomes
The study found that regadenoson was remarkably well-tolerated. There were zero instances of sinus node dysfunction or high-degree atrioventricular (AV) block in the transplant group, even though 44% of tests were conducted within the first two years post-transplant—the period of peak sensitivity. Minor side effects like dyspnea and headache occurred at rates comparable to the general population.
Beyond safety, the imaging results provided significant prognostic value. Patients with an abnormal stress CMR (indicating ischemia or dysfunction) had a significantly higher risk of future health crises. Specifically, the cumulative incidence of MACE over three years was 32.1% for those with abnormal results, compared to just 12.7% for those with normal results ($p = 0.034$).
Discussion and Future Directions
These findings suggest that regadenoson stress CMR is a viable, non-invasive tool for the long-term surveillance of heart transplant recipients. Its ability to bypass the denervated heart's sensitivity while providing clear prognostic signals marks a significant advancement over adenosine-based protocols.
However, the study's retrospective nature and relatively small sample size (57 patients) are limitations. Furthermore, the lack of universal correlation with invasive "gold standard" angiography means the exact sensitivity for CAV detection requires further validation. Future multi-center prospective studies are needed to determine if regadenoson stress CMR can eventually replace invasive surveillance in standard post-transplant care.
Summary updated